TRPV2 and neoplasm: Furthermore, after excising tumours and other major organs at 24 h post injection (Supplementary Fig. 10c), TRPV2 antibody-functionalised nanoparticles (TRPV2–PCNH) were mainly accumulated in tumours overexpressing TRPV2 (HT-29–TRPV2), with more than two-fold higher radiant efficiency than in HT-29 control tumours and vital organs such as liver, lung, spleen, heart and kidney (Supplementary Fig. 10d).